Pacqué M, Muñoz B, Greene B M, White A T, Dukuly Z, Taylor H R
Dana Center for Preventive Ophthalmology, Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lancet. 1990 Jun 9;335(8702):1377-80. doi: 10.1016/0140-6736(90)91253-7.
In a study of the safety, acceptability, and efficacy of ivermectin for community-based mass treatment of onchocerciasis, the drug was issued twice, one year apart, to the population of a rubber plantation (14,000 people) in Liberia, where over 80% of the adults have Onchocerca volvulus infection. The plantation microfilarial load in a sample of adults was reduced by 86% 6 months after initial treatment and by 78% after 1 year. Compliance was 97% with each round of treatment. After the initial treatment of 7699 people, 101 (1.3%) had moderate adverse reactions. After re-treatment only 37 (0.5%) people had moderate adverse reactions. No ivermectin-related death or severe adverse reactions occurred. The data show that community-based treatment with ivermectin is well accepted and effective in reducing microfilarial loads. Ivermectin is likely to provide the first realistic means of chemotherapy-based control of onchocerciasis on a mass scale.
在一项关于伊维菌素用于社区大规模治疗盘尾丝虫病的安全性、可接受性和疗效的研究中,该药物在相隔一年的时间里分两次发放给利比里亚一个橡胶种植园(14000人)的居民,该种植园80%以上的成年人感染了盘尾丝虫。初始治疗6个月后,成年样本中的种植园微丝蚴负荷降低了86%,1年后降低了78%。每轮治疗的依从性为97%。在对7699人进行初始治疗后,101人(1.3%)出现中度不良反应。再次治疗后,只有37人(0.5%)出现中度不良反应。未发生与伊维菌素相关的死亡或严重不良反应。数据表明,基于社区的伊维菌素治疗很容易被接受,并且在降低微丝蚴负荷方面有效。伊维菌素可能是大规模基于化疗控制盘尾丝虫病的首个切实可行的手段。